Investigating the benefits of cannabinoids for agitation in Alzheimer's patients
LifeâÂÂs end Benefits of CannaBidol and TetrahYdrocannabinol (LiBBY) Trial
This study is looking at how well a mix of two cannabis compounds, THC and CBD, can help reduce agitation in people with Alzheimer's and other dementias who are in hospice care, aiming to find a safer option than the usual medications that can have tough side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-10408165 on NIH RePORTER |
What this research studies
This research aims to explore the effectiveness of a combination of two cannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD), in treating agitation in patients with Alzheimer's disease and other types of dementia who are eligible for hospice care. Conducted within the Alzheimer's Clinical Trials Consortium, the study will involve multiple clinical sites to ensure a robust approach to patient care. The goal is to provide a safer alternative to current psychoactive medications, which often have significant side effects. By focusing on this vulnerable population, the research seeks to improve quality of life during end-of-life care.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with Alzheimer's disease or other types of dementia who are experiencing agitation and are eligible for hospice care.
Not a fit: Patients with mild cognitive impairment or those not experiencing agitation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for managing agitation in patients with Alzheimer's disease.
How similar studies have performed: Previous research has shown promise in using cannabinoids for various neurological conditions, suggesting potential for success in this novel application.
Where this research is happening
Charleston, United States
- Medical University of South Carolina — Charleston, United States (Active)
Researchers
- Principal investigator: Mintzer, Jacobo — Medical University of South Carolina
- Study coordinator: Mintzer, Jacobo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.